Sabina Eigenbrod

Munich, BY 81377, Germany

Last Updated: 09/26/2026

Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 27 publications

The number of methylated CpG sites within the MGMT promoter region linearly correlates with outcome in glioblastoma receiving alkylating agents.

The number of methylated CpG sites within the MGMT promoter region linearly correlates with outcome in glioblastoma receiving alkylating agents.

Journal: Acta neuropathologica communications
Published: January 27, 2021

MGMT promoter methylation is not correlated with integrin expression in malignant gliomas: clarifying recent clinical trial results.

MGMT promoter methylation is not correlated with integrin expression in malignant gliomas: clarifying recent clinical trial results.

Journal: Medical oncology (Northwood, London, England)
Published: May 28, 2018

Substitutions of PrP N-terminal histidine residues modulate scrapie disease pathogenesis and incubation time in transgenic mice.

Substitutions of PrP N-terminal histidine residues modulate scrapie disease pathogenesis and incubation time in transgenic mice.

Journal: PloS one
Published: July 22, 2017

Overexpression of cytosolic, plasma membrane bound and extracellular heat shock protein 70 (Hsp70) in primary glioblastomas.

Overexpression of cytosolic, plasma membrane bound and extracellular heat shock protein 70 (Hsp70) in primary glioblastomas.

Journal: Journal of neuro-oncology
Published: April 30, 2017

Outcome in unresectable glioblastoma: MGMT promoter methylation makes the difference.

Outcome in unresectable glioblastoma: MGMT promoter methylation makes the difference.

Journal: Journal of neurology
Published: October 28, 2016

Quantifying prion disease penetrance using large population control cohorts.

Quantifying prion disease penetrance using large population control cohorts.

Journal: Science translational medicine
Published: January 22, 2016

Biological tumor volume in 18FET-PET before radiochemotherapy correlates with survival in GBM.

Biological tumor volume in 18FET-PET before radiochemotherapy correlates with survival in GBM.

Journal: Neurology
Published: January 23, 2015

Prognostic significance of dynamic 18F-FET PET in newly diagnosed astrocytic high-grade glioma.

Prognostic significance of dynamic 18F-FET PET in newly diagnosed astrocytic high-grade glioma.

Journal: Journal of nuclear medicine : official publication, Society of Nuclear Medicine
Published: December 25, 2014

Dynamic 18F-FET PET in suspected WHO grade II gliomas defines distinct biological subgroups with different clinical courses.

Dynamic 18F-FET PET in suspected WHO grade II gliomas defines distinct biological subgroups with different clinical courses.

Journal: International journal of cancer
Published: May 13, 2014

Molecular stereotactic biopsy technique improves diagnostic accuracy and enables personalized treatment strategies in glioma patients.

Molecular stereotactic biopsy technique improves diagnostic accuracy and enables personalized treatment strategies in glioma patients.

Journal: Acta neurochirurgica
Published: January 16, 2014

Male sex as a risk factor for the clinical course of skull base chordomas.

Male sex as a risk factor for the clinical course of skull base chordomas.

Journal: Journal of neurosurgery
Published: January 11, 2014

Dynamic 18F-FET PET in newly diagnosed astrocytic low-grade glioma identifies high-risk patients.

Dynamic 18F-FET PET in newly diagnosed astrocytic low-grade glioma identifies high-risk patients.

Journal: Journal of nuclear medicine : official publication, Society of Nuclear Medicine
Published: January 01, 2014
Showing 1-12 of 27

Last Updated: 09/26/2026